TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean change in stepping motor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in brain neuronal activations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of CGM placement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Circulating concentrations of Amylyn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in post-traumatic stress symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vitamin D3 serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in S-NoMAD score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score in the Multiple choice test questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Disease-Free Survival (DFS) at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: DLTs occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Acute pancreatitis recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Cognitive function (SCD-9)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Cognitive function (MoCA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Cognitive function (AD8)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Cognitive function (CDR)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of enlicitide decanoate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of enlicitide decanoate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Half-Life (t1/2) of enlicitide decanoate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPH subscale of the MSQoL-54
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peripheral blood components related to efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intracranial progression free-survival
Endpoint domain: Mortality/survival
Primary endpoint: Adverse Drug Reaction incidence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Zarit Burden Index
Endpoint domain: Life impact
Endpoint subdomain: Caregiver burden
Primary endpoint: Relation Quality Index Caregiver
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Caregiver Strain Index
Endpoint domain: Life impact
Endpoint subdomain: Caregiver burden
Primary endpoint: Accuracy of AI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of expert with or without AI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of non-expert with or without AI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VR-12 mental health score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reproducibility of rapid decrement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of serious treatment-emergent adverse events (serious TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum plasma concentration (Cmax) of donzakimig
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with viral load below 20 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: North Star Ambulation Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney Function Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Subjective IKDC score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total Morphine Sulfate Use in Milligrams
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent total body weight loss at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with ≥5 percent total body weight loss at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, frequency, and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of Safety and Tolerability by Adverse Event Monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients that reach EASI50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in Doppler flow patterns of hepatic veins, portal vein, and intra-renal veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Diagnosis of acute heart failure (HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 2-year recurrence free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Percent of mineralized tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone volume in the reconstructed cleft site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients receiving RBC transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in ovulation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of postoperative mortality
Endpoint domain: Mortality/survival
Primary endpoint: In-hospital surgery-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: rate of adverse event attributable to the surgery
Endpoint domain: Adverse events/effects
Primary endpoint: rate of adverse event attributable to the antibiotic treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients Alive and Free of Respiratory Failure at Day 28
Endpoint domain: Mortality/survival
Primary endpoint: Transfertest score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in IIEF-5 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in penile hardness using SWE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Topical tolerability as assessed by the dermatologist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Improvement from Baseline in Acne and Comedones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Negative Emotion Regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Alcohol Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Cannabis Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Aggression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Physical Symptom Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Psychosocial Symptom Status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Cognitive Symptom Status
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in participant's rate of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PDL1 modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PET after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Gait Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measured Recovery of Train of Four
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Venous valve sinus forward flow volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Venous valve sinus reversing flow volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Deep vein centerline flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hepato-renal index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat percentage evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular outline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cases of SBP (Spontaneous Bacterial Peritonitis)
Endpoint domain: Adverse events/effects
Primary endpoint: Greying Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamstring pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean BP change (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feasibility of the Intervention Scale
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the Intervention Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Appropriateness of the Intervention Scale
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Presence and number of post-operatory complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients achieving Composite Clinical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of musculoskeletal injuries (MSKIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Recent sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Loco-regional control rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean placebo-corrected change from baseline in systolic blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tepotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Time of Last Measurable Concentration (AUC0-tlast) of Tepotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of WCM app
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of WCM app
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of appropriate and inappropriate interfacility transfers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence and Nature of Treatment-Related Adverse Events (AE) or Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: pathological response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Drooling Impact Scale (DIS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from anxiety and stress level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composition of gut metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Composition of metabolites in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composition of proteins in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in mini-Mental Adjustment to Cancer Scale (mini-MAC) at Week 8
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline in Cognitive Assessment for Chemo Fog Research (CAB-CF) at Week 8
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline in the Functionality Assessment Instrument in Cancer Treatment - Cognitive Function (FACT-COG) at Week 8
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Phrenic nerve function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Perception of care among intensive care nurses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perception of unmet care among intensive care nurses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of reduction in menstrual blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoarthritis Index (WOMAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: plasma BD-tau levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Minimal effective concentration of lidocaine solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery from iron deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change score of Sit to stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change score of 10 Meter walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change score of Timed up and Go Test (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change score of 6 Minute walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change score of Barthel Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Decision to withhold or withdraw intensive care
Endpoint domain: Adverse events/effects
Primary endpoint: Change in superficial temporal artery (STA) diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vascular access outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Feasibility of Daily Practice
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of Immediate Post-Intervention Follow-Up Assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of 6-Week Follow-Up Assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Movement of the lower limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline in liver panel parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FEV1% (Forced Expiratory Volume in 1 second percentage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neck Disability Pain Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of seizure free study participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of variants of Nasal septum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of variants of nasal cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receiving any own mother's milk at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receiving any own mother's milk on day 14 of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe NEC requiring surgery or resulting in death
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants who do not receive diagnostic audiological testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: serum Endothelin-1 (ET-1) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of lung ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity of lung ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Specificity of lung ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tumoral Mass Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of depressive symptoms score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: olfactory threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work-related risks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Density Lipoprotein (LDL) Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High Density Lipoprotein (HDL) Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of life impact in HIV patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Lymphocyte/neutrophil ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in total oxidation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in oxidative stress index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defined infection resulting in hospital admission
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of PRS and VS
Endpoint domain: Adverse events/effects
Primary endpoint: 6-minute race test (meters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in vein diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in the depth of the fistula from the epidermis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in brachial artery blood flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GastroIntestinal Quality of Life Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: change in sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: change in insomnia related to postmenopausal symptoms
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Rate of completed fetoscopic procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fetal survival at birth
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy Assessment-ORR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EMG onset during functional reaching task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EMG amplitude during functional reaching task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in movement onset on functional reaching task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of auditory hallucinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in beliefs about voices in schizophrenia spectrum disorder
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants who experience adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adverse events (AEs) by severity
Endpoint domain: Adverse events/effects
Primary endpoint: Electrocardiogram (EEG) data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-measured blood glucose (SMBG) data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Continuous glucose monitoring (CGM) data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak stress myocardial blood (mg/ml/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global and regional Circumferential strain (GCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early detection of endolymphatic hydrops
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prep-and-bonding time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline depression at Week 8
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline anxiety at Week 8
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline stress at Week 8
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Spatial span backwards performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life measured by EuroQOL5D-5L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life